Curcumin-loaded PLGA nanoparticles conjugated with anti-P-glycoprotein antibody to overcome multidrug resistance

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 21, 2014, Pages 9249-9258

  Punfa, Wanisa ^a,b   Suzuki, Shugo ^b   Pitchakarn, Pornsiri ^a   Yodkeeree, Supachai ^a   Naiki, Taku ^b   Takahashi, Satoru ^b   Limtrakul, Pornngarm ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Curcumin; Multidrug resistance; Nanoparticles; Targeting drug delivery

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIOMATERIAL; CURCUMIN; LACTIC ACID; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOLOGY; MOUSE; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOCOMPATIBLE MATERIALS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOPARTICLES; P-GLYCOPROTEIN; PACLITAXEL; POLYGLYCOLIC ACID; UTERINE CERVICAL NEOPLASMS;

EID: 84918536142     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.21.9249     Document Type: Article

References (42)

1. Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006). Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev, 58, 1688-713.
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007). Bioavailability of curcumin: problems and promises. Mol Pharm, 4, 807-18.
3. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002). Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol, 64, 573-82.
4. Bain LJ, McLachlan JB, LeBlanc GA (1997). Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect, 105, 812-8.
5. Burgio DE, Gosland MP, McNamaraa PJ (1998). Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther, 287, 911-7.
6. Chang G (2003). Multidrug resistance ABC transporters. FEBS Letters, 555, 102-5.
7. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P (2004). Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol, 68, 2043-52.
8. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res, 14, 1310-6.
9. CIOMS (1985). International guiding principles for biomedical research involving animals. Altern Lab Anim, 12, 2.
10. Cirstoiu-Hapca A, Buchegger F, Lange N, et al (2010). Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J Control Release, 144, 324-31.
11. Cisternino S, Rousselle C, Debray M, Scherrmann JM (2004). In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier. Pharm Res, 21, 1382-9.
12. Dai X-Z, Yin H-T, Sun L-F, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
13. Gallo JM, Li S, Guo P, Reed K, Ma J (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res, 63, 5114-7.
14. Hu YP, Pourquier P, Doignon F, Crouzet M, Robert J (1996). Effects of modulators of multidrug resistance on the expression of the MDR1 gene on human KB cells in culture. Anticancer Drugs, 7, 738-44.
15. Iangcharoen P, Punfa W, Yodkeeree S, et al (2011). Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment. Arch Pharm Res, 34, 1679-89.
16. Jang SH, Wientjes MG, Au JL (2001). Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther, 298, 1236-42.
17. Kiziltepe T, Ashley JD, Stefanick JF, et al (2012). Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J, 2, 64.
18. Lazzari S, Moscatelli D, Codari F, et al (2012). Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res, 14, 920.
19. Limtrakul P, Khantamat O, Pintha K (2004). Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol, 54, 525-30.
20. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65, 271-84.
21. Makadia HK, Siegel SJ (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel), 3, 1377-97.
22. Manjunath K, Venkateswarlu V (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 107, 215-28.
23. Mechetner EB, Roninson IB (1992). Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A, 89, 5824-8.
24. Meng H, Mai WX, Zhang H, et al (2013). Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano, 7, 994-1005.
25. Ohara Y, Oda T, Yamada K, et al (2012). Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int J Cancer, 131, 2402-10.
26. Oyagbemi AA, Saba AB, Ibraheem AO (2009). Curcumin: from food spice to cancer prevention. Asian Pac J Cancer Prev, 10, 963-7.
27. Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P (2012). Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin, 33, 823-31.
28. Qiao WJ, Cheng HY, Li CQ, et al (2011). Identification of pathways involved in paclitaxel activity in cervical cancer. Asian Pac J Cancer Prev, 12, 99-102.
29. Qureshi S, Shah AH, Ageel AM (1992). Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med, 58, 124-7.
30. Sadauskas E, Wallin H, Stoltenberg M, et al (2007). Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol, 4, 10.
31. Shehzad A, Wahid F, Lee YS (2010). Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm, 343, 489-99.
32. Shen F, Chu S, Bence AK, et al (2008). Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther, 324, 95-102.
33. Song Z, Feng R, Sun M, et al (2011). Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci, 354, 116-23.
34. Tabatabaei Mirakabad FS, Nejati-Koshki K, Akbarzadeh A, et al (2014). PLGA-Based Nanoparticles as Cancer Drug Delivery Systems. Asian Pac J Cancer Prev, 15, 517-35.
35. Torchilin VP (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4, 145-60.
36. Tsai YM, Chien CF, Lin LC, Tsai TH (2011). Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm, 416, 331-8.
37. Wang W, Zhu R, Xie Q, et al (2012). Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine, 7, 3667-77.
38. Yadav D, Anwar MF, Garg V, et al (2014). Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac J Cancer Prev, 15, 2335-40.
39. Yamate J, Tatsumi M, Nakatsuji S, et al (1993). Immunohistochemical observations of macrophages and perisinusoidal cells in carbon tetrachloride-induced rat liver injury. J Vet Med Sci, 55, 973-7.
40. Yin H-T, Zhang D-G, Wu X-L, Huang X-E, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12.
41. Zhang C, Qu G, Sun Y, et al (2008). Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials, 29, 1233-41.
42. Zhang L, Gu FX, Chan JM, et al (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther, 83, 761-9.